the Image

Open Cancer Clinical Trials

The University of Chicago Medicine Comprehensive Cancer Center is leading the way in biomedical discoveries that will help physicians fight cancer more effectively. Our dedicated researchers and clinicians are conducting clinical trials in phases I, II, III and IV, leading to the development of new and better treatments. To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email cancerclinicaltrials@bsd.uchicago.edu .

Transplant (Hematologic) Cancer Clinical Trials
Interventional only

Phase III
Study No PI Title
CIRB16-1320 Artz, Andrew A051301: A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Details
Phase II
Study No PI Title
IRB16-1508 Artz, Andrew A Single-Cohort, Phase II Study of Ruxolitinib in Combination With Corti-Costeroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
IRB15-0866 Artz, Andrew The Rapid Study: Randomized (RA) Phase (P) II Study To Expedite Allogeneic Transplant With Immediate (I) Haploidentical Plus Unrelated Cord Donor (D) Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients. Details
IRB14-1106 Mullane, Kathleen A Phase 2b, Randomized, Double-Blind, Placebo Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS 5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract (GS-US-218-0108) Details
IRB14-1109 Mullane, Kathleen A Phase 2b, Randomized, Double-Blind, Placebo Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS 5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract (GS-US-218-1502) Details
IRB13-1280 Artz, Andrew A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Age 50 or Older with Intermediate-2 and High Risk Myelodysplastic Syndrome Details
IRB12-1191 Liu, Hongtao Pilot study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Details
Phase I
Study No PI Title
IRB16-1437 Bishop, Michael A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects with Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
IRB16-0888 Liu, Hongtao Phase I Study to Assess the Tolerability and Efficacy of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients with Hematological Malignancies after Allogeneic Stem Cell Transplantation
IRB14-0709 Liu, Hongtao A Phase I Study Of Intensity Modulated Total Marrow Irradiation (IMTMI) In Addition To Fludarabine/Melphelan Conditioning For Allogeneic Transplantation For Advanced Hematologic Malignancies Details
Others
Study No PI Title
IRB16-1195 Kline, Justin Pilot study of pembrolizumab treatment for disease relapse after allogeneic stem cell transplantation
IRB12-1924 Artz, Andrew A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA) Details
10-551-B Bishop, Michael Pilot study T cell depletion in the setting of autologous stem cell transplantation for patients with multiple myeloma Details
IRB16-0441 Artz, Andrew Assessing Physical Fitness in Cancer Patients with Cardiopulmonary Exercise Testing and Wearable Data Generation.
IRB14-0883 Bishop, Michael A Multicenter Study Of Apheresis Collection Of Peripheral Blood Mononuclear Cells (PBMC) In Patients With CD19 Expressing Malignancies Who Could Be Eligible For A CTL019 Clinical Research Trial
IRB15-0536 Artz, Andrew Novel Prognostication in Hematopoietic Cell Transplantation (HCT).
IRB15-0095 Bishop, Michael Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy
12-1856 Marino, Susana The University of Chicago Transplant Immunology and Immunogenetics Laboratory Research Registry and Specimen Collection Protocol for Biomedical Research
10-064-B Godley, Lucy Molecular characterization of hematopoietic malignancies
15953A Artz, Andrew Protocol for a research database for hematopoietic Stem Cell Transplanation and Marrow Toxic Injuries _ REPLACES 13239B Details
15961A Artz, Andrew Protocol for a Research Sample Repository For Allogeneic Hematopioetic Stem Cell Transplanation_ REPLACES 12590A
15147A Artz, Andrew Collection of Research Blood and/or Marrow Samples in Donors Undergoing Bone Marrow, Stem Cell or Lymphocyte Collection.
12993B Thirman, Michael Collection and Use of Mobilized Peripheral Blood Stem Cells from Patients with Hematologic Malignancies


Although our objective is to provide on updated listings of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.

Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT Team .